Research in my laboratory focuses on crosstalk between estrogen receptors and p53 signaling in breast, lung, and ovarian cancers. Inactivation of p53 by multiple mechanisms is a frequent event in these cancers. Estrogen receptors alpha (ERα) and beta (ERβ) have important roles in normal and disease physiology of these organs. We have shown that both ERα and ERβ bind p53. Binding of ERα to p53 results in functional inactivation of p53, whereas ERβ-p53 interaction elicits context-dependent effects in cancer cells.